definiens: means any improvement made by ( including on behalf of ) Sangamo or [ * * * ] during the term of theAgreement ( whether or not such improvement is patentable ) to ZFNs and associated reagents ( including, without limitation, expression plasmids and Donor Sequences ) and/or Sangamo Know - How ( including methodologies / protocols for creating ZFNModified Cell Lines ), where such improvement would improve by [ * * * ] the ( a ) efficiency of creating ZFN Modified CellLines ; ( b ) time taken to create ZFN Modified Cell Lines ; and/or ( c ) activity of any ZFN Reagent . For purposes of thisdefinition, refers to : ( i ) transfer efficiency, in terms of percent of cells that uptake ZFN Reagents by transfectionor comparable procedure ; or ( ii ) frequency of targeted [ * * * ] in a Designated Gene within a population of cells, after deliveryof ZFN Reagent(s ) to such population . For purposes of this definition, refers to the time taken from delivery of aZFN Reagent(s ) to a cell line to the identification of a clone in which a Designated Gene has been Functionally [ * * * ] . Forpurposes of this definition, refers to : ( i ) DNA binding activity or strength of the DNA binding domain of a ZFN;(ii ) DNA cleavage activity of the nuclease domain of a ZFN Reagent ; ( iii ) in vivo activity in terms of percent of cells in whicha Designated Gene has been Functionally [ * * * ], after delivery of ZFN Reagent(s ) to such cells ; or ( iv ) frequency ofhomologous recombination with Donor Sequences